Why Advicenne's Kidney Disease Drug Reverted To Standard EU Review
Executive Summary
The CEO of French firm Advicenne explains why the company did not win an accelerated EU assessment for its kidney disease drug ADV7103, and why it may well try again in future with another indication – and perhaps with other new drugs too.
You may also be interested in...
Stemline Has What It Takes On EU Fast-Track Front
There's good news for Stemline Therapeutics on the EU fast-track front. At least three other companies, though, have had their requests rejected in recent months and Novartis is not saying whether a request it made was successful or not.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.